Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

June 3, 2018 – Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line postmenopausal patients with HR+/HER2- advanced breast cancer[1] – In

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

June 2, 2018 – ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna® – Findings further support durability and safety of TFR with Tasigna; nearly all patients who lost

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

May 30, 2018 – Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (IST) – Regulatory action underscores the treatment

Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®

May 28, 2018 – Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)1 – These improvements were reported early by Entresto patients, with

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

May 18, 2018 Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related peptide receptor (CGRP-R), which plays an important role

Novartis data at ASCO and EHA reinforce company’s commitment to reimagining cancer

May 17, 2018 Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be presented at ASCO Long-term analyses of Tasigna® Treatment-free Remission (TFR) studies in

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

May 16, 2018 Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new, distinctive platform capabilities Alcon returning to a position of

Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

May 12, 2018 New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS)[1] In a landmark controlled Phase III study of children and adolescents (ages 10 to

Essential Consultants – Novartis statement

May 9, 2018 – 17:15 CET (updated May 11, 2018 – 22:30 CET) In February 2017, shortly after the election of President Trump, we entered into a one-year agreement with Essential Consultants. With the recent change in administration, Novartis believed

Machine learning poised to accelerate drug discovery / Charlie Schmidt / Novartis

Technology used to tag friends on social media could change the way drug discovery is done. By Charlie Schmidt / May 07, 2018 A technology called machine learning is behind that seemingly magical ability of social networking websites to identify

Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab

Holzkirchen, May 2, 2018 – Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing Application (BLA) for its proposed biosimilar rituximab. Sandoz stands behind the

Novartis provides update on proposed acquisition of AveXis

Basel, May 1, 2018 – Novartis AG (NYSE: NVS) (“Novartis”) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) applicable to Novartis’ cash tender offer for AveXis, Inc. (NASDAQ: AVXS) (“AveXis”) has expired. As

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only CAR-T therapy FDA-approved for two distinct indications – in non-Hodgkin

Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma

Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection Tafinlar + Mekinist significantly reduced the risk of disease recurrence or death compared